ACAD
NASDAQACADIA Pharmaceuticals Inc.
News · 26 weeks570%
2026-03-012026-08-23
Mix2290d
- Insider11(50%)
- Other5(23%)
- SEC Filings3(14%)
- Earnings2(9%)
- Leadership1(5%)
Latest news
25 items- PREuropean Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European UnionAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). "The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need," said Catherine Owen Adams, Acadia’s Chief Executive Officer. "For people living with Rett syndro
- INSIDEREVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. exercised 20,141 shares at a strike of $17.84 and sold $587,242 worth of shares (20,141 units at $29.16) as part of a pre-agreed trading plan (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- SECSEC Form SCHEDULE 13G filed by ACADIA Pharmaceuticals Inc.SCHEDULE 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
- SECACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- PRAcadia Pharmaceuticals Reports Second Quarter 2026 Financial Results- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis - Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million - Topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis anticipated September to October 2026 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the second quarter ended June 30, 2026. "Acadia delivered
- INSIDEREVP, Head of Research & Dev Thompson Elizabeth H.Z. converted options into 32,272 shares and sold $432,663 worth of shares (16,558 units at $26.13) as part of a pre-agreed trading plan, increasing direct ownership by 479% to 18,994 units (SEC Form 4) (tax withholding)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- PRAcadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth ConferenceAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-app
- PRAcadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies -- RADIANT Phase 2 enrollment completed, with topline results now expected September to October 2026 and Phase 3 screening and enrollment underway Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Fast Track designation is designed to facilita
- PRAcadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in
- PRAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer-- Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia’s executive leadership team. "Carl is a proven global leader with a strong track record of building high-performing organizations and shaping culture to enable business performance," said
- INSIDERPRINCIPAL ACCOUNTING OFFICER Kihara James sold $297,912 worth of shares (11,421 units at $26.08) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 13,088 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- PRDAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP-- European Commission decision expected in the coming months -- If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would b
- SECSEC Form S-8 filed by ACADIA Pharmaceuticals Inc.S-8 - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- INSIDERDirector Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Ndu Adora converted options into 8,107 shares, increasing direct ownership by 33% to 32,908 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Daly James M converted options into 8,107 shares, increasing direct ownership by 201% to 12,148 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Brege Laura converted options into 8,107 shares, increasing direct ownership by 54% to 23,202 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Garofalo Elizabeth A. converted options into 8,107 shares, increasing direct ownership by 32% to 33,489 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERDirector Poole Jonathan converted options into 2,010 shares (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- SECACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- INSIDERPRINCIPAL ACCOUNTING OFFICER Kihara James sold $114,393 worth of shares (5,401 units at $21.18), decreasing direct ownership by 18% to 24,509 units (SEC Form 4)4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- SECSEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.10-Q - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- SECACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- PRAcadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis - Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis between August and October 2026 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the first quarter ended March 31, 2026. "Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million," said Catherine Owen Adams, C
ACAD FAQ
7 questionsWhat does ACADIA Pharmaceuticals Inc. do?
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor...Where does ACAD stock trade?
ACADIA Pharmaceuticals Inc. (ACAD) is listed on NASDAQ.What sector and industry is ACAD in?
ACADIA Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ACADIA Pharmaceuticals Inc. go public?
ACADIA Pharmaceuticals Inc. (ACAD) completed its IPO in 1985.What are analysts saying about ACAD?
ACADIA Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy with a $2900.00 price target on 2026-03-25. Recent price targets range from $2000.00 to $3500.00.What companies are similar to ACAD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ACAD side-by-side with any of them on Quantisnow.How can I track ACAD on Quantisnow?
Quantisnow aggregates ACADIA Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACAD to receive live email and push alerts on every new disclosure.